MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A
Agostinho G Rocha,Antonietta Franco,Andrzej M Krezel,Jeanne M Rumsey,Justin M Alberti,William C Knight,Nikolaos Biris,Emmanouil Zacharioudakis,James W Janetka,Robert H Baloh,Richard N Kitsis,Daria Mochly-Rosen,R Reid Townsend,Evripidis Gavathiotis,Gerald W Dorn,Agostinho G. Rocha,Andrzej M. Krezel,Jeanne M. Rumsey,Justin M. Alberti,William C. Knight,James W. Janetka,Robert H. Baloh,Richard N. Kitsis,R. Reid Townsend,Gerald W. Dorn
DOI: https://doi.org/10.1126/science.aao1785
IF: 56.9
2018-04-20
Science
Abstract:An innovative approach for a rare disease Charcot-Marie-Tooth disease type 2A (CMT2A) is a rare, inherited neurodegenerative condition. Affected individuals develop severe progressive muscle weakness, motor deficits, and peripheral neuropathy. Although defects in the gene encoding mitofusin 2 (MFN2) are known to cause CMT2A, the disease remains incurable. Rocha et al. identified specific MFN2 residues contributing to the disease and developed a class of MFN2-agonist drugs. The small molecules restored mitochondrial fusion and activity in the sciatic nerves of mice; they may also help in other diseases linked to mitochondrial trafficking. Science , this issue p. 336
multidisciplinary sciences